39.34
-0.21(-0.53%)
Currency In USD
| Previous Close | 39.55 |
| Open | 38.84 |
| Day High | 39.94 |
| Day Low | 38.37 |
| 52-Week High | 43.73 |
| 52-Week Low | 3.72 |
| Volume | 2.09M |
| Average Volume | 3.24M |
| Market Cap | 5.6B |
| PE | -19.19 |
| EPS | -2.05 |
| Moving Average 50 Days | 28.92 |
| Moving Average 200 Days | 13.92 |
| Change | -0.21 |
If you invested $1000 in Cogent Biosciences, Inc. (COGT) since IPO date, it would be worth $885.24 as of December 23, 2025 at a share price of $39.34. Whereas If you bought $1000 worth of Cogent Biosciences, Inc. (COGT) shares 5 years ago, it would be worth $3,097.64 as of December 23, 2025 at a share price of $39.34.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Cogent Biosciences Announces Positive Top-line Results of APEX Trial of Bezuclastinib in Patients with Advanced Systemic Mastocytosis (AdvSM)
GlobeNewswire Inc.
Dec 08, 2025 12:30 PM GMT
-- Bezuclastinib demonstrated rapid and deep clinical benefit in AdvSM patients resulting in an objective response rate (CR+CRh+PR+CI) of 57% per mIWG criteria and 80% per PPR criteria -- -- Bezuclastinib demonstrated a powerful effect on mast cell b
Cogent Biosciences Presents Full SUMMIT Results of Bezuclastinib in Patients with NonAdvanced Systemic Mastocytosis (NonAdvSM) at the 67th Annual Meeting of the American Society of Hematology (ASH)
GlobeNewswire Inc.
Dec 06, 2025 2:30 PM GMT
-- Bezuclastinib achieves clear clinical benefit across all symptom domains including significant improvements on 11 individual symptoms plus the most severe symptom at baseline -- -- Bezuclastinib demonstrates that reducing objective measures of di
Cogent Biosciences Announces Pricing of Concurrent Public Offerings of Common Stock and 1.625% Convertible Senior Notes Due 2031
GlobeNewswire Inc.
Nov 12, 2025 4:16 AM GMT
WALTHAM, Mass. and BOULDER, Colo., Nov. 11, 2025 (GLOBE NEWSWIRE) -- Cogent Biosciences, Inc. (“Cogent”) (Nasdaq: COGT), a biotechnology company focused on developing precision therapies for genetically defined diseases, today announced the pricing